Salarius Pharmaceuticals, Inc. SLRX

Full chart Compare
Set alert

Price alert · SLRX

All alert types
0.84 USD 0.00 (+0.00%)

At closeJan 7, 2026, 4:00 PM EST

0.83 -0.01 -1.18%

After hours · Jan 7, 4:00 PM ET

0.6865 Day range 0.8976

52-week range unavailable

YTD
+29.47%
1 year
-96.73%
Market cap
4.92M
Shares out
1.44M
Forward P/E
-0.17
YTD return
+29.47%
1-year return
-96.73%
Volume
5.96M
Open
0.706
Previous close
0.84
Day's range
0.6865 – 0.8976
Beta
0.93

2Y -78.2302 (-98.96%)

0.000025.000050.000075.0000Mar 24Aug 24Jan 25Jun 25Oct 250.8198

Key statistics

Enterprise value
-1.26M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.15
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-6.13M
Total cash
3.27M
Total debt
0
Return on equity
-119.83%
Short % of float
4.55%
50-day average
1.52
200-day average
2.59

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
SLRX Revenue — quarterly 0
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
SLRX Net income — quarterly -873.47K
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
SLRX EPS — quarterly -1.81
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025

Earnings

SLRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.76——
Aug 9, 2024Jun 1, 2024-53.60-2.37+51.23+95.58%
May 13, 2024Mar 1, 2024-53.60-3.28+50.32+93.88%
Mar 22, 2024Dec 1, 2023-8.08-1.76+6.32+78.22%
Nov 9, 2023Sep 1, 2023-8.56-5.20+3.36+39.25%
Aug 10, 2023Jun 1, 2023-10.08-11.44-1.36-13.49%

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SLRX — it syncs with the Stock Master app.

Insider holders

SLRX insider holders
InsiderRelationLatest transactionDateShares held
ARTHUR DAVID JChief Executive OfficerStock Award(Grant)Feb 12, 202349,135
BURLESON TESSDirectorStock Award(Grant)Jan 2, 20232,722
HANISH ARNOLD CDirectorStock Award(Grant)Jan 2, 20233,294
LAMMERS PAUL IDirectorStock Award(Grant)Jan 2, 20231,718
LIEBER JONATHAN IDirectorStock Award(Grant)Jan 2, 20232,940
MCCREEDY BRUCE J JRDirectorStock Award(Grant)Jan 2, 20231,788

Institution ownership

SLRX institution ownership
Holder% heldSharesValueReported
Tower Research Capital LLC (TRC)0.22%3,1895.01KSep 29, 2024
Citigroup Inc.0.11%1,6102.53KSep 29, 2024
UBS Group AG0.02%260408Sep 29, 2024
Osaic Holdings Inc0.01%162254Sep 29, 2024
Blackrock Inc.0.00%11Sep 29, 2024
Bank of America Corporation0.00%1828Sep 29, 2024

Fund ownership

SLRX fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.40%5,7389.01KOct 30, 2024
Listed Funds Tr-Horizon Kinetics Medical ETF0.26%3,7235.84KSep 29, 2024
Fidelity Series Total Market Index Fund0.15%2,1383.36KOct 30, 2024
Vanguard Extended Market Index Fund0.13%1,8202.86KSep 29, 2024
Fidelity Total Market Index Fund0.02%321503Oct 30, 2024